Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
Kubo T, Tsurita G, Hirohashi Y, Yasui H, Ota Y, Watanabe K, Murai A, Matsuo K, Asanuma H, Shima H, Wada S, Nakatsugawa M, Kanaseki T, Tsukahara T, Mizuguchi T, Hirata K, Takemasa I, Imai K, Sato N, Torigoe T. Kubo T, et al. Among authors: asanuma h. Cancer Sci. 2019 Aug;110(8):2386-2395. doi: 10.1111/cas.14099. Epub 2019 Jul 11. Cancer Sci. 2019. PMID: 31206934 Free PMC article. Clinical Trial.
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, Nagai I, Sato N, Hiratsuka H. Miyazaki A, et al. Among authors: asanuma h. Cancer Sci. 2011 Feb;102(2):324-9. doi: 10.1111/j.1349-7006.2010.01789.x. Epub 2010 Dec 10. Cancer Sci. 2011. PMID: 21143701 Free article. Clinical Trial.
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, Tokita S, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nakae Y, Sugita O, Ito YM, Ota Y, Kimura Y, Kutomi G, Hirata K, Mizuguchi T, Imai K, Takemasa I, Sato N, Torigoe T. Shima H, et al. Among authors: asanuma h. Cancer Sci. 2019 Aug;110(8):2378-2385. doi: 10.1111/cas.14106. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31218770 Free PMC article. Clinical Trial.
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N. Idenoue S, et al. Among authors: asanuma h. Clin Cancer Res. 2005 Feb 15;11(4):1474-82. doi: 10.1158/1078-0432.CCR-03-0817. Clin Cancer Res. 2005. PMID: 15746049
Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variant 4.
Nakatsugawa M, Hirohashi Y, Torigoe T, Asanuma H, Takahashi A, Inoda S, Kiriyama K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, Shijubo N, Honda R, Nomura N, Hasegawa T, Takahashi H, Sato N. Nakatsugawa M, et al. Among authors: asanuma h. Cancer Sci. 2009 Aug;100(8):1485-93. doi: 10.1111/j.1349-7006.2009.01187.x. Epub 2009 May 19. Cancer Sci. 2009. PMID: 19459848 Free PMC article.
Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.
Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, Asanuma H, Tsuruma T, Terui T, Ishitani K, Ohmura T, Wang Q, Greene MI, Hasegawa T, Hirata K, Sato N. Inoda S, et al. Among authors: asanuma h. J Immunother. 2009 Jun;32(5):474-85. doi: 10.1097/CJI.0b013e3181a1d109. J Immunother. 2009. PMID: 19609239
The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N. Inoda S, et al. Among authors: asanuma h. Exp Mol Pathol. 2011 Feb;90(1):55-60. doi: 10.1016/j.yexmp.2010.10.001. Epub 2010 Oct 13. Exp Mol Pathol. 2011. PMID: 20950610
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, Nakatsugawa M, Nishizawa S, Tamura Y, Tsuruma T, Terui T, Kondo T, Ishitani K, Hasegawa T, Hirata K, Sato N. Inoda S, et al. Among authors: asanuma h. Am J Pathol. 2011 Apr;178(4):1805-13. doi: 10.1016/j.ajpath.2011.01.004. Am J Pathol. 2011. PMID: 21435460 Free PMC article.
HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.
Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, Kanaseki T, Kamiguchi K, Asanuma H, Morita R, Sokolovskaya A, Matsuzaki J, Yamada R, Fujii R, Kampinga HH, Kondo T, Hasegawa T, Hara I, Sato N. Nishizawa S, et al. Among authors: asanuma h. Cancer Res. 2012 Jun 1;72(11):2844-54. doi: 10.1158/0008-5472.CAN-11-3062. Epub 2012 May 2. Cancer Res. 2012. PMID: 22552285 Free article.
671 results